Endogenous peptide

Angiotensin-(1-7)

An endogenous renin-angiotensin-system peptide with vasodilatory, anti-inflammatory and antifibrotic actions in experimental models. Therapeutic administration remains investigational.

Sequence
Asp-Arg-Val-Tyr-Ile-His-Pro
Formula
C41H62N12O11
Molecular weight
899.0 Da

Evidence confidence

Human
2/5
Some human clinical evidence
1 citation
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
2/5
Partially characterised safety
1 citation

Claimed uses

Mechanisms

Safety notes

Potential risks include hypotension, dizziness and unpredictable interaction with renin-angiotensin-system medicines. Long-term dosing and product quality are not established.

Regulation
  • Not approved as a general cardiovascular, renal, pulmonary or performance medicine.

References

  1. Phase I and pharmacokinetic study of angiotensin-1-7, an endogenous antiangiogenic hormone · 2009
Last reviewed
11 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.